What question did this study set out to answer?

This study aims to determine if baseline hepcidin levels can predict the response to iron therapy in patients with active inflammatory bowel disease.

June 11, 2026Alimentary Pharmacology & TherapeuticsOpen Access

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial

View Full Paper

Ask AI

Bookmark

Authors

LKLola J. M. KoppelmanLeiden University Medical Center RLRoberta LoveikyteUniversity Medical Center Groningen RGRogier L. GoetgebuerAmsterdam University Medical Centers

Discussion

Member takes

Implication

Randomized trial evaluates hepcidin's ability to predict iron therapy response in inflammatory bowel disease, suggesting personalized treatment options.

Key Points

This study aims to determine if baseline hepcidin levels can predict the response to iron therapy in patients with active inflammatory bowel disease.
Ninety adults with active inflammatory bowel disease and iron deficiency were randomly assigned to receive IV iron, oral ferrous fumarate, or oral ferric maltol.
Response to treatment was assessed at 12 weeks based on specific hemoglobin and iron levels.
Predictive performance was evaluated using logistic regression and receiver operating characteristic analyses.
Baseline hepcidin strongly predicted response: AUC for ferrous fumarate was 0.86 (95% CI: 0.71–1.00) and for IV iron was 0.63 (95% CI: 0.30–0.96).
Hepcidin > 2.68 μg/mL had 89% sensitivity and 77% specificity in identifying non-responders to ferrous fumarate.
Higher transferrin/log 10 (ferritin) ratios significantly increased response likelihood (OR: 2.95, 95% CI: 1.38–6.30).

Cite This Study

Koppelman et al. (2026) studied this question.

synapsesocial.com/papers/6a2a515980c8f91e7f39d96f https://doi.org/10.1111/apt.70775

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates hepcidin's ability to predict iron therapy response in inflammatory bowel disease, suggesting personalized treatment options.

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider